Laura Hamill
CIK: 0001751804
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Aug 31, 2026JAZZ
Jazz Pharmaceuticals plc
Tax Payment(F)Direct14 shares at avg. $244.06$3K - Aug 31, 2026JAZZ
Jazz Pharmaceuticals plc
Tax Payment(F)Direct1.7K shares at avg. $241.39$408K - Aug 5, 2026JAZZ
Jazz Pharmaceuticals plc
Award(A)Direct1.6K shares- - Jun 12, 2026FATE
FATE THERAPEUTICS INC
Award(A)DirectStock Option (Right to Buy)
175.8K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Disposition(D)Direct25.1K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Tender Offer(U)Direct5.8K shares at avg. $8.60$50K - Aug 8, 2025JAZZ
Jazz Pharmaceuticals plc
Tax Payment(F)Direct1.8K shares at avg. $111.25$201K - Aug 7, 2025JAZZ
Jazz Pharmaceuticals plc
Award(A)Direct3.5K shares- - Jun 30, 2025YMAB
Y-mAbs Therapeutics, Inc.
Award(A)Direct25.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 31, 2026 |  JAZZ Jazz Pharmaceuticals plc | Tax Payment(F) | 14 | $244.06 | $3,417 | Direct |
| Aug 31, 2026 | JAZZ Jazz Pharmaceuticals plc | Tax Payment(F) | 1,692 | $241.39 | $408,432 | Direct |
| Aug 5, 2026 | JAZZ Jazz Pharmaceuticals plc | Award(A) | 1,605 | - | $0 | Direct |
| Jun 12, 2026 |  FATE FATE THERAPEUTICS INC | Award(A) Stock Option (Right to Buy) | 175,800 | - | - | Direct |
| Sep 16, 2025 |  YMAB Y-mAbs Therapeutics, Inc. | Disposition(D) | 25,080 | - | - | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Tender Offer(U) | 5,825 | $8.60 | $50,095 | Direct |
| Aug 8, 2025 | JAZZ Jazz Pharmaceuticals plc | Tax Payment(F) | 1,805 | $111.25 | $200,807 | Direct |
| Aug 7, 2025 | JAZZ Jazz Pharmaceuticals plc | Award(A) | 3,507 | - | - | Direct |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Award(A) | 25,080 | - | - | Direct |
1-9 of 9 transactions
About Hamill Laura
Hamill Laura (SEC CIK 0001751804) files insider reports with the SEC as Director of Jazz Pharmaceuticals plc (JAZZ), Director of FATE THERAPEUTICS INC (FATE) and Director of Y-mAbs Therapeutics, Inc. (YMAB).
Signal8 holds 7 ownership filings by Hamill Laura (1 Form 3, 6 Form 4), filed between Jul 2, 2025 and Sep 2, 2026. Those filings report 9 transactions, from Jun 30, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hamill Laura's filings is in DUBLIN 4.
Recent filings by Hamill Laura
- Aug 31, 2026: Tax withholdings of JAZZ shares (2 lines, Form 4, code F).
- Aug 5, 2026: Grant or award of JAZZ shares (Form 4, code A).
- Jun 12, 2026: Grant or award of FATE derivative securities (Form 4, code A).
- Sep 16, 2025: Disposition to issuer transaction of YMAB shares (Form 4, code D).
- Sep 16, 2025: Tender of shares transaction of YMAB shares (Form 4, code U).
Other insiders filing for Jazz Pharmaceuticals plc (JAZZ)
- GALA RENEE D, President & CEO
- COZADD BRUCE C, Director
- Patil Neena M, EVP & Chief Legal Officer
- Henderson Mary Elizabeth, SVP, Technical Operations
- Smith Mark Douglas, Director
- RIEDEL NORBERT G, Director